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Plasma gastric inhibitory polypeptide and
glucagon-like peptide-1 levels after glucose
loading are associated with different factors
in Japanese subjects
Norio Harada, Akihiro Hamasaki, Shunsuke Yamane, Atsushi Muraoka, Erina Joo, Kazuyo Fujita, Nobuya Inagaki*
ABSTRACT
Aims/Introduction: Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are major incretins that potentiate
insulin secretion from pancreatic b-cells. The factors responsible for incretin secretion have been reported in Caucasian subjects,
but have not been thoroughly evaluated in Japanese subjects. We evaluated the factors associated with incretin secretion during oral
glucose tolerance test (OGTT) in Japanese subjects with normal glucose tolerance (NGT).
Materials and Methods: We measured plasma GIP and GLP-1 levels during OGTT in 17 Japanese NGT subjects and evaluated the
factors associated with GIP and GLP-1 secretion using simple and multiple regression analyses.
Results: GIP secretion (AUC-GIP) was positively associated with body mass index (P < 0.05), and area under the curve (AUC) of
C-peptide (P < 0.05) and glucagon (P < 0.01), whereas GLP-1 secretion (AUC-GLP-1) was negatively associated with AUC of plasma
glucose (P < 0.05). The insulinogenic index was most strongly associated with GIP secretion (P < 0.05); homeostasis model
assessment b-cell was the most the strongly associated factor in GLP-1 secretion (P < 0.05) among the four indices of insulin
secretion and insulin sensitivity.
Conclusions: Several distinct factors might be associated with GIP and GLP-1 secretion during OGTT in Japanese subjects.
(J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00078.x, 2011)
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INTRODUCTION
Oral glucose administration leads to greater insulin release from
pancreatic islets than intravenous glucose loading that yields
equivalent glucose levels. Gut hormonal substances released in
response to glucose include the incretins, gastric inhibitory
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which
are responsible for 50–60% of postprandial insulin secretion1.
GIP is secreted on meal ingestion from K-cells in the proximal
small intestine, whereas GLP-1 is secreted from L-cells in the
distal small intestine and colon, and binds to their respective
receptors (GIP receptor [GIPR] and GLP-1 receptor) on the
surface of pancreatic b-cells to stimulate insulin secretion by
increasing the intracellular adenosine 3¢,5¢-monophosphate
(cAMP) concentration2–4.
Type 2 diabetes is characterized by both decreased insulin
secretion and reduced insulin sensitivity5–7. The incretin effect
has been shown to be reduced in type 2 diabetic subjects com-
pared with those with normal glucose tolerance (NGT) in previ-
ous studies8,9, suggesting that a reduced incretin effect might be
associated with hyperglycemia after food intake and glucose
loading in type 2 diabetes. When intravenous infusion of GIP or
GLP-1 was carried out in type 2 diabetic subjects, GLP-1 poten-
tiated insulin secretion from pancreatic b-cells, but GIP did not,
showing that the GIPR signal is downregulated in b-cells in type
2 diabetes10. In studies using rodent models, it was reported that
GIPR mRNA and protein expression levels in islets are
decreased in the diabetic state11. In contrast, in the non-diabetic
obese state, GIP plays an important role in maintaining blood
glucose levels12. The GIP signal might be enhanced as a result
of increased GIPR sensitivity of b-cells to GIP or increased GIP
secretion from K-cells in the non-diabetic obese state. Indeed,
GIP concentrations are reported to be increased in obese rodent
models and human subjects compared with those in lean
rodents and human subjects, respectively13–15. Furthermore, we
have previously shown the hypersensitivity of GIPR to GIP in
b-cells of high fat-induced obese mice16. Plasma GLP-1 concen-
trations in type 2 diabetic patients are reported to be reduced
after meal ingestion and glucose loading9,17. However, in other
studies it was reported that GLP-1 concentrations did not differ
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in NGT and type 2 diabetic subjects18–20. Thus, the measure-
ment of GIP and GLP-1 concentrations in various metabolic
states is important to evaluate the effects of incretin on insulin
secretion.
Insulin sensitivity in Asian subjects has been shown to be
higher than in Mexican Americans and Caucasians in previous
reports21,22, which is partly as a result of the fact that Asians,
including Japanese, are generally less obese. Furthermore, insulin
secretion rather than insulin sensitivity is the more important fac-
tor in progression from NGT to diabetes in Japanese subjects23.
We have reported that early-phase insulin secretion is consider-
ably decreased, even in Japanese NGT subjects with 1-h plasma
glucose (PG) levels during oral glucose tolerance test (OGTT) of
more than 180 mg/dL24. Thus, it is especially important to evalu-
ate incretin secretion and determine the factors associated with
incretin secretion in Japanese NGT subjects, because GIP and
incretin is responsible for more than 50% of postprandial insulin
secretion after glucose ingestion. The factors responsible for
incretin secretion have been reported in Caucasian subjects, but
have not been thoroughly elucidated in Japanese subjects.
In the present study, we evaluated GIP and GLP-1 levels dur-
ing OGTT and determined the factors involved in GIP and
GLP-1 secretion (area under the curve [AUC] of GIP and
GLP-1 during OGTT) in Japanese NGT subjects.
MATERIALS AND METHODS
Subjects
We recruited 17 Japanese healthy volunteers. The subjects had
no history of hypertension, hyperlipidemia or kidney and liver
diseases, and did not take any drugs 2 weeks before the study.
The study was designed in compliance with the ethics regula-
tions of the Helsinki Declaration and Kyoto University.
Informed consent was obtained from all subjects.
Study Procedure
The subjects’ age, height and bodyweight were determined.
Blood samples for the measurement of liver and kidney func-
tion, HbA1c, serum triglyceride (TG), total cholesterol and high-
density lipoprotein (HDL)-cholesterol levels were drawn after an
overnight fast. All subjects received OGTT. After the subjects
fasted overnight for 10–16 h, standard OGTT with 75 g glucose
was given according to the National Diabetes Data Group rec-
ommendations25. NGT was diagnosed according to World
Health Organization (WHO) criteria26.
Blood samples were collected at )15, 0, 10, 20, 30, 60, 90,
120, 150 and 180 min after glucose loading and were centri-
fuged at 1800 g at 4C for 10 min. After collecting supernatant
of the samples, plasma and serum were stocked at )80C.
Plasma GIP, GLP-1 levels and the various parameters (PG,
serum immunoreactive insulin [IRI], serum C-peptide reactivity
[CPR], TG, serum free fatty acid [FFA] and plasma glucagon)
were measured at the indicated times (plasma GIP and GLP-1
levels were measured at )15, 0, 10, 30, 60, 90, 120 and 180 min
after glucose loading, and plasma glucagon levels were measured
at )15, 0, 30, 60, 90, 120 and 180 min after glucose loading).
The PG levels were measured by glucose oxidase method. Serum
IRI levels were measured by two-site radioimmunoassay. Total
GIP and total GLP-1 levels were measured using human GIP
ELISA kit (Linco Research, St Charles, MO, USA; range of
detection from 8.2 pg/mL to 2000 pg/dL) and human GLP-1
ELISA kit (Meso Scale Discovery, Gaithersburg, MD, USA;
range of detection from 2.4 pg/mL to 1,000,000 pg/dL), respec-
tively, as previously described27,28. The AUC of PG, IRI, CPR,
TG, FFA, glucagon, total GIP (AUC-GIP) and total GLP-1
(AUC-GLP-1) were calculated. We then analyzed the relation-
ship between the AUC of GIP (GIP secretion) and GLP-1
(GLP-1 secretion) and age, body mass index (BMI) and the
parameters during OGTT.
Statistical Analysis
Basal insulin secretion and sensitivity were evaluated by homeo-
stasis model assessment (HOMA) b-cell function and homeosta-
sis model assessment of insulin resistance (HOMA-IR)29,30,
respectively. Early-phase insulin secretion and systemic insulin
sensitivity during OGTT were evaluated by insulinogenic
index31 and insulin sensitivity index (ISI) composite32. The cal-
culations of the four indices were as follows:
HOMO b-cell ¼ 20 fasting IRI level ðFIRIÞ ðpmol/LÞ=
ðfasting PG level ½FPG ½mmol/L  3:5Þ
HOMO-IR ¼ FIRI ðpmol/LÞ  FPG ðmmol/LÞ=22:5
Insulinogenic index ¼ð30 min IRI FIRI ½pmol/LÞ=
ð30 min PG FPG ½mmol/LÞ
IRI composite ¼ 10;000=ðFGP ½mg/dL  FIRI ½lU/mL
meanOGTTPG ½mg/dL
meanOGTT IRI ½lU/mLÞ0:5
All analyses were carried out using statistical analysis software
(SPSS version 17.0, IBM, Somers, NY, USA) system. Statistical
analysis was carried out by ANOVA with Fisher’s PLSD test for
changing levels of GIP, GLP-1, and the parameters during OGTT
and differences between the two groups were assessed by
unpaired t-test. We used simple regression analysis to determine
the relationship between AUC-GIP or AUC-GLP-1 and the age,
BMI and the parameters during OGTT, and we carried out multi-
ple regression analysis to determine the factors most strongly
associated with AUC-GIP and AUC-GLP-1, and the indices of
insulin secretion and sensitivity. Probability (P) values <0.05 were
considered statistically significant. Data are presented as
mean ± standard error (SE).
RESULTS
Table 1 shows clinical characteristics of the subjects. Mean age
was 31.7 ± 1.3 years and mean BMI was 23.1 ± 0.9 kg/m2. No
subjects had liver or kidney dysfunction. HbA1c, FPG, TG, total
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cholesterol and HDL-cholesterol levels were within normal lim-
its in the fasting state.
The levels of GIP, GLP-1, PG, IRI, CPR, TG, FFA and gluca-
gon after glucose loading were measured (Figure 1). The sub-
jects were diagnosed NGT according to WHO criteria with
fasting plasma glucose and 2-h glucose levels below 6.1 and
7.8 mmol/L, respectively. Levels of PG, IRI and CPR were sig-
nificantly increased from 10 min after glucose loading compared
with fasting level (Figure 1a–c). FFA levels were significantly
decreased from 10 min after glucose loading (Figure 1d). TG
levels were not significantly changed during OGTT (Figure 1e).
Glucagon levels were significantly decreased from 30 min after
glucose loading (Figure 1f). Total GIP levels were significantly
increased from 10 min during OGTT (Figure 1g). Total GLP-1
levels were significantly increased from 10 min during OGTT
with peaks at 30 and 120 min (Figure 1h).
We analyzed the relationship between AUC-GIP or AUC-
GLP-1 and age, BMI and the several parameters (AUC of PG,
IRI, CPR, TG, FFA and glucagon). AUC-GIP were positively
related to BMI and AUC of CPR, IRI and glucagon, but
AUC-GLP-1 was not related to these factors (Figure 2a–c; AUC
data of IRI during OGTT are not shown; P < 0.05). In contrast,
AUC-GLP-1 was inversely related to AUC of PG (Figure 2d),
but AUC-GIP was not.
We then analyzed the relationship between AUC-GIP or
AUC-GLP-1 and indices of insulin secretion and insulin sensi-
tivity. AUC-GIP was positively related to insulinogenic index
and HOMA-IR, whereas AUC-GLP-1 was positively related to
HOMA b-cell function (Figure 3a–c). ISI composite was not
related to either AUC-GIP or AUC-GLP-1 (Figure 3d). In addi-
tion, multiple regression analysis was carried out to determine
the factors strongly associated with AUC-GIP and AUC-GLP.
The insulinogenic index was the most strongly associated factor
in AUC-GIP (correlation coefficients 0.56, standardized b 0.56,
P < 0.05) of the four indices; HOMA b-cell function was the
strongest factor in AUC-GLP-1 (HOMA b-cell function: corre-
lation coefficients 0.524, standardized b 0.870, P < 0.01, ISI
composite: correlation coefficients 0.063, standardized b 0.581,
P < 0.05).
DISCUSSION
In the present study, we estimated the incretin level after glucose
loading in Japanese NGT subjects and found that plasma GIP
and GLP-1 levels during OGTT are related to different factors.
Incretin action of GIP is reduced in the diabetic state as a
result of decreased GIP receptor expression on pancreatic
b-cells11, whereas GIP signaling is enhanced and maintains
Table 1 | Clinical characteristics of the subjects
n (male/female) 17 (14/3)
Age (years) 31.7 ± 1.3
Body mass index (kg/m2) 23.1 ± 0.9
Fasting plasma glucose (mmol/L) 6.1 ± 0.2
Fasting insulin (pmol/L) 25.2 ± 3.7
HbA1c (%) 4.7 ± 0.0
Triglycerides (mmol/L) 2.00 ± 0.31
Total cholesterol (mmol/L) 4.56 ± 0.16
HDL-cholesterol (mmol/L) 1.51 ± 0.10
Insulinogenic index 66.22 ± 8.54
HOMA b-cell 60.85 ± 8.89
HOMA-IR 0.94 ± 0.15
ISI composite 11.45 ± 1.67
Means ± SE. HDL, high-density lipoprotein; HOMA, homeostasis
model assessment; HOMA-IR, homeostasis model assessment of insulin
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Figure 1 | Concentrations of (a) plasma glucose, (b) serum immunoreactive insulin, (c) serum C-peptide reactivity (CPR), (d) serum free fatty acid
(FFA), (e) serum triglyceride (TG), (f) glucagon, (g) total gastric inhibitory polypeptide (GIP) and (h) total glucagon-like peptide-1 (GLP-1) during oral
glucose tolerance test in 17 Japanese subjects. Mean ± SE, *P < 0.05, **P < 0.01, ***P < 0.001 vs the levels at fasting.
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glucose homeostasis by compensatory increased insulin secretion
in the obese state15,16. In some human studies in Caucasians,
plasma GIP levels are increased in obese subjects14,15 and there
is a positive relationship between AUC-GIP and AUC of FFA
during OGTT18. In the present study, AUC-GIP after glucose
loading was not associated with AUC of FFA, but was positively
associated with BMI, HOMA-IR, and AUC of IRI and CPR
after glucose loading. In fact, obese subjects are known to have
hyperinsulinemia and insulin resistance33,34, and BMI was
strongly associated with AUC of IRI and CPR. Thus, GIP secre-
tion from K-cells may well be associated with insulin resistance
to maintain postprandial hyperinsulinemia in Japanese NGT
subjects. It is unknown why there was no correlation between
AUC-GIP and AUC-glucose. It might be explained by the fact
that GIP secretion is associated with the amount of glucose
loading1, whereas blood glucose levels are maintained within
normal levels by GIP-induced compensatory insulin secretion in
NGT subjects.
GLP-1 secretions of type 2 diabetes subjects after glucose or
meal ingestion are diverse in human studies9,17–19. Some studies
report that GLP-1 secretion is decreased in Caucasian type 2
diabetes9,17. Recently, it is reported that GLP-1 levels after inges-
tion of glucose and mix meal in Japanese type 2 diabetic sub-
jects were not decreased compared with those in NGT subjects,
suggesting that GLP-1 secretion is not decreased in Japanese
type 2 diabetes20,35,36. Two studies of Caucasian subjects found
that AUC-GLP-1 during OGTT is positively associated with age
and AUC of glucagon, whereas AUC of GLP-1 is negatively
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Figure 2 | Simple regression analysis of gastric inhibitory polypeptide
secretion (AUC-GIP) and (a) body mass index (BMI), (b) AUC of serum
C-peptide reactivity (CPR) and (c) glucagon. (d) Simple regression
analysis of glucagon-like peptide-1 secretion (AUC-GLP-1) and AUC of
plasma glucose (PG).
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Figure 3 | Relationship between gastric inhibitory polypeptide secretion (AUC-GIP) and glucagon-like peptide-1 secretion (AUC-GLP-1) and the
indices of insulin secretion and insulin sensitivity. (a) Insulinogenic index, (b) homeostasis model assessment (HOMA) b-cell function, (c) homeostasis
model assessment of insulin resistance (HOMA-IR) and (d) insulin sensitivity index (ISI) composite. Ns, not significant.
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present study, AUC-GLP-1 was negatively related to AUC of
PG during OGTT, showing that the increase in GLP-1 secretion
after glucose loading is associated with a decrease in postpran-
dial glucose levels in Japanese NGT subjects. It has been
reported that GLP-1 levels after glucose loading are positively
related to gastric empting in Caucasian subjects37. Although we
did not measure gastric empting of the subjects in the present
study, increasing GLP-1 secretion after glucose loading might
decrease postprandial glucose levels through gastric emptying.
In the present study, BMI and AUC of FFA were not associated
with AUC-GLP-1 during OGTT. Obese subjects have higher
FFA levels than lean subjects38. However, because Japanese sub-
jects are less obese than Caucasian subjects21, the difference
observed in the relationship between AUC-GIP and GLP-1, and
AUC of FFA might reflect this ethnic difference in Caucasians
and Japanese.
Insulin secretion, rather than insulin sensitivity, is the more
important factor in the progression from NGT to type 2 diabe-
tes in Japanese patients23,39. Because incretin is an intestinal
hormone that induces postprandial insulin secretion1, we
hypothesize that GIP and GLP-1 secretion is more crucial in
Japanese subjects than in Caucasian subjects. Indeed, GLP-1
mimetics and DPP-4 inhibitors improve glycemic control better
in Japanese type 2 diabetic patients than in Caucasian type 2
diabetic patients in clinical trials40–43. We therefore evaluated
the correlation between GIP secretion (AUC-GIP) and GLP-1
secretion (AUC-GLP-1), and the indices of insulin secretion and
insulin sensitivity in Japanese NGT subjects during OGTT. The
values of HOMA b-cell, insulinogenic index, HOMA-IR and ISI
composite were similar to those in previous studies of Japanese
subjects24,30,39. AUC-GIP was positively associated with the insu-
linogenic index and HOMA-IR, and the insulinogenic index
was strongly associated with AUC-GIP, whereas AUC-GLP-1
was associated only with HOMA b-cell among the four indices.
It has been reported that early-phase insulin secretion is an
important factor in the progression from NGT through
impaired glucose tolerance (IGT) to type 2 diabetes39, and that
basal insulin secretion (HOMA b-cell) and insulin resistance are
important factors in the progression from NGT through
impaired fasting glucose (IFG) to type 2 diabetes in Japanese
patients44. Thus, enhancing the GIP and GLP-1 signals might
be particularly useful in inhibiting the progression of type 2 dia-
betes in Japanese patients. Recently, variants at the GIP receptor
gene locus associated with 2-h glucose levels during OGTT were
identified by meta-analysis of genome-wide association studies45.
In subjects who carry this GIP receptor risk allele, early-phase
insulin secretion is decreased. These data seem to support our
results that GIP secretion is associated with insulinogenic index
in Japanese NGT subjects.
In conclusion, we evaluated plasma GIP and GLP-1 levels
during OGTT in Japanese NGT subjects. GLP-1 secretion was
associated with PG during OGTT, and basal insulin secretion
(HOMA b-cell) and GIP secretion was associated with BMI and
early-phase insulin secretion (insulinogenic index). Thus, there
might be different factors associated with GIP and GLP-1 secre-
tion during OGTT in Japanese subjects.
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